182 related articles for article (PubMed ID: 19836372)
1. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
[TBL] [Abstract][Full Text] [Related]
2. Differential role of EGF and BFGF in human GBM-TIC proliferation: relationship to EGFR-tyrosine kinase inhibitor sensibility.
Bajetto A; Porcile C; Pattarozzi A; Scotti L; Aceto A; Daga A; Barbieri F; Florio T
J Biol Regul Homeost Agents; 2013; 27(1):143-54. PubMed ID: 23489694
[TBL] [Abstract][Full Text] [Related]
3. The EGFRvIII variant in glioblastoma multiforme.
Gan HK; Kaye AH; Luwor RB
J Clin Neurosci; 2009 Jun; 16(6):748-54. PubMed ID: 19324552
[TBL] [Abstract][Full Text] [Related]
4. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling.
Chakravarti A; Loeffler JS; Dyson NJ
Cancer Res; 2002 Jan; 62(1):200-7. PubMed ID: 11782378
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression.
Micallef J; Taccone M; Mukherjee J; Croul S; Busby J; Moran MF; Guha A
Cancer Res; 2009 Oct; 69(19):7548-56. PubMed ID: 19773446
[TBL] [Abstract][Full Text] [Related]
7. EGF receptor-targeted synthetic double-stranded RNA eliminates glioblastoma, breast cancer, and adenocarcinoma tumors in mice.
Shir A; Ogris M; Wagner E; Levitzki A
PLoS Med; 2006 Jan; 3(1):e6. PubMed ID: 16318410
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
9. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
[TBL] [Abstract][Full Text] [Related]
10. Delivery systems and molecular targets of mechanism-based therapies for GBM.
Phuphanich S; Brat DJ; Olson JJ
Expert Rev Neurother; 2004 Jul; 4(4):649-63. PubMed ID: 15853584
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
12. PDGF receptor alpha inhibition induces apoptosis in glioblastoma cancer stem cells refractory to anti-Notch and anti-EGFR treatment.
Cenciarelli C; Marei HE; Zonfrillo M; Pierimarchi P; Paldino E; Casalbore P; Felsani A; Vescovi AL; Maira G; Mangiola A
Mol Cancer; 2014 Nov; 13():247. PubMed ID: 25380967
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
14. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
[TBL] [Abstract][Full Text] [Related]
15. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
16. Combination of a ptgs2 inhibitor and an epidermal growth factor receptor-signaling inhibitor prevents tumorigenesis of oligodendrocyte lineage-derived glioma-initiating cells.
Hide T; Takezaki T; Nakatani Y; Nakamura H; Kuratsu J; Kondo T
Stem Cells; 2011 Apr; 29(4):590-9. PubMed ID: 21360625
[TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer.
Khalil MY; Grandis JR; Shin DM
Expert Rev Anticancer Ther; 2003 Jun; 3(3):367-80. PubMed ID: 12820779
[TBL] [Abstract][Full Text] [Related]
18. Differential gene expression analysis reveals generation of an autocrine loop by a mutant epidermal growth factor receptor in glioma cells.
Ramnarain DB; Park S; Lee DY; Hatanpaa KJ; Scoggin SO; Otu H; Libermann TA; Raisanen JM; Ashfaq R; Wong ET; Wu J; Elliott R; Habib AA
Cancer Res; 2006 Jan; 66(2):867-74. PubMed ID: 16424019
[TBL] [Abstract][Full Text] [Related]
19. A truncated soluble epidermal growth factor receptor-Fc fusion ligand trap displays anti-tumour activity in vivo.
Adams TE; Koziolek EJ; Hoyne PH; Bentley JD; Lu L; Lovrecz G; Ward CW; Lee FT; Scott AM; Nash AD; Rothacker J; Nice EC; Burgess AW; Johns TG
Growth Factors; 2009 Jun; 27(3):141-54. PubMed ID: 19333814
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
